L. Varghese

发表

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea

E. Han, J. Song, Tae Hyun Kim, 2018, PharmacoEconomics.

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future

B. Standaert, L. Varghese, C. Sauboin, 2020, Journal of market access & health policy.

A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand

L. Varghese, B. Mungall, Xu-Hao Zhang, 2018, Applied Health Economics and Health Policy.

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis

K. Holl, D. Curran, L. Varghese, 2018, Dermatology and Therapy.

Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster

B. Yawn, B. Patterson, P. Buck, 2017 .

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults

M. Ganz, D. Curran, L. Varghese, 2019, Applied Health Economics and Health Policy.

Response to Wu et al. — Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong

L. Varghese, B. Hoet, B. Mungall, 2016, Human vaccines & immunotherapeutics.

Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.

B. Yawn, B. Patterson, P. Buck, 2018, Vaccine.

Health economic assessment of a rabies pre-exposure prophylaxis program compared to post-exposure prophylaxis alone in high-risk age groups in the Philippines.

B. Quiambao, Piyali Mukherjee, L. Varghese, 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Applying a Constrained Optimization Portfolio Model to Aid Prioritization of Public Health Interventions in Malaysia.

B. Standaert, L. Varghese, I. Van Vlaenderen, 2020, Value in health regional issues.

Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK.

F. van Kessel, D. Curran, A. Guignard, 2017, Public health.

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

D. Curran, L. Varghese, A. von Krempelhuber, 2018, Human vaccines & immunotherapeutics.

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany

T. Mrkvan, D. Curran, L. Varghese, 2017, Human vaccines & immunotherapeutics.

The temporal impact of aging on the burden of herpes zoster

D. Curran, B. Standaert, A. Olivieri, 2017, BMC Geriatrics.

Disparities in Naltrexone Prescriptions to Medicaid Enrollees During the COVID-19 Pandemic

B. Piper, L. Varghese, H. A. Subervi, 2022, medRxiv.

Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore.

D. Sim, L. Varghese, S. Linden, 2023, Value in health regional issues.

Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018

L. Varghese, J. Olbrecht, Shehzad Iqbal, 2018, Infectious Diseases and Therapy.

Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam - findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model.

L. Varghese, PohWan Chang, Sorrakorn Juntarasiripas, 2024, Journal of medical economics.

Meeting Abstracts - Academy of Managed Care Pharmacy Nexus 2017.

L. Varghese, J. Carrico, Bruce Y. Lee, 2017, Journal of managed care & specialty pharmacy.